| Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions M Lafourcade, T Larrieu, S Mato, A Duffaud, M Sepers, I Matias, ... Nature neuroscience 14 (3), 345-350, 2011 | 361 | 2011 |
| Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex M Lafourcade, I Elezgarai, S Mato, Y Bakiri, P Grandes, OJ Manzoni PloS one 2 (8), e709, 2007 | 277 | 2007 |
| Targeting the endocannabinoid system in the treatment of fragile X syndrome A Busquets-Garcia, M Gomis-González, T Guegan, C Agustín-Pavón, ... Nature medicine 19 (5), 603-607, 2013 | 264 | 2013 |
| A single in-vivo exposure to Δ9THC blocks endocannabinoid-mediated synaptic plasticity S Mato, V Chevaleyre, D Robbe, A Pazos, PE Castillo, OJ Manzoni Nature neuroscience 7 (6), 585-586, 2004 | 255 | 2004 |
| Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain S Mato, E Del Olmo, A Pazos European Journal of Neuroscience 17 (9), 1747-1754, 2003 | 249 | 2003 |
| A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens L Fourgeaud, S Mato, D Bouchet, A Hémar, PF Worley, OJ Manzoni Journal of Neuroscience 24 (31), 6939-6945, 2004 | 219 | 2004 |
| Presynaptic homeostatic plasticity rescues long-term depression after chronic Δ9-tetrahydrocannabinol exposure S Mato, D Robbe, N Puente, P Grandes, OJ Manzoni Journal of Neuroscience 25 (50), 11619-11627, 2005 | 121 | 2005 |
| Astroglial connexin43 contributes to neuronal suffering in a mouse model of Alzheimer’s disease C Yi, X Mei, P Ezan, S Mato, I Matias, C Giaume, A Koulakoff Cell Death & Differentiation 23 (10), 1691-1701, 2016 | 112 | 2016 |
| Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain S Mato, A Pazos, EM Valdizán European journal of pharmacology 443 (1-3), 43-46, 2002 | 96 | 2002 |
| CB1 knockout mice display impaired functionality of 5‐HT1A and 5‐HT2A/C receptors S Mato, E Aso, E Castro, M Martín, O Valverde, R Maldonado, Á Pazos Journal of neurochemistry 103 (5), 2111-2120, 2007 | 92 | 2007 |
| Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine1A receptor … S Mato, R Vidal, E Castro, Á Díaz, Á Pazos, EM Valdizán Molecular pharmacology 77 (3), 424-434, 2010 | 89 | 2010 |
| Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo A Bernal‐Chico, M Canedo, A Manterola, M Victoria Sánchez‐Gómez, ... Glia 63 (1), 163-176, 2015 | 87 | 2015 |
| Cannabidiol induces intracellular calcium elevation and cytotoxicity in oligodendrocytes S Mato, M Victoria Sánchez‐Gómez, C Matute Glia 58 (14), 1739-1747, 2010 | 78 | 2010 |
| Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens S Mato, M Lafourcade, D Robbe, Y Bakiri, OJ Manzoni Neuropharmacology 54 (1), 87-94, 2008 | 76 | 2008 |
| Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain S Mato, A Pazos Neuropharmacology 46 (5), 716-726, 2004 | 65 | 2004 |
| CB1 cannabinoid receptor‐dependent and ‐independent inhibition of depolarization‐induced calcium influx in oligodendrocytes S Mato, E Alberdi, C Ledent, M Watanabe, C Matute Glia 57 (3), 295-306, 2009 | 57 | 2009 |
| Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model M Gomis-González, A Busquets-Garcia, C Matute, R Maldonado, S Mato, ... Genes 7 (9), 56, 2016 | 49 | 2016 |
| Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation P Ramos-Gonzalez, S Mato, JC Chara, A Verkhratsky, C Matute, ... npj Parkinson's Disease 7 (1), 31, 2021 | 43 | 2021 |
| Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination A Manterola, A Bernal-Chico, R Cipriani, M Canedo-Antelo, ... Biochemical pharmacology 157, 189-201, 2018 | 37 | 2018 |
| Zn2+‐induced ERK activation mediates PARP‐1‐dependent ischemic‐reoxygenation damage to oligodendrocytes M Domercq, S Mato, FN Soria, MV Sánchez‐gómez, E Alberdi, C Matute Glia 61 (3), 383-393, 2013 | 36 | 2013 |
